BiotechTube

FOLFIRI + OSE2101

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer

Trial Timeline

Apr 10, 2021 → Dec 1, 2025

NCT ID
NCT03806309

About FOLFIRI + OSE2101

FOLFIRI + OSE2101 is a phase 2 stage product being developed by OSE Immunotherapeutics for Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03806309. Target conditions include Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03806309Phase 2Active

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
77
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33

Other Products from OSE Immunotherapeutics

OSE2101 + DocetaxelPhase 3
69
OSE2101 + Docetaxel + PemetrexedPhase 3
69
OSE-127 + PlaceboPhase 2
44
FR104Phase 1/2
33
Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negativePhase 1/2
33